Rafael Medical gets FDA approval

In 2006, Rafael Medical raised $2.5 million at a company value of $16 million from Possis Medical.

Rafael Medical Technologies Ltd. has obtained US Food and Drug Administration (FDA) marketing approval for its SafeFlo Vena Cava Filter. The approval is for the permanent implantation of the filter in patients at risk of pulmonary embolism; safety and effectiveness as a retrievable or temporary filter have not been established.

Rafael Medical obtained EU CE Mark certification for the filter for both permanent and removal options in 2004.

The SafeFlo filter is an implanted expandable metal device used to capture hazardous blood clots caused by trauma, surgery or other medical conditions before they can reach the lungs, causing a pulmonary embolism. SafeFlo's design provides a double ring anchoring mechanism as an alternative to the standard strut-based designs of filters available on the market since the 1970s.

In late 2006, Rafael Medical raised $2.5 million at a company value of $16 million from Possis Medical Inc. (Nasdaq: POSS), which develops and makes cardiovascular and vascular treatment devices.

Published by Globes [online], Israel business news - www.globes-online.com - on May 21, 2009

© Copyright of Globes Publisher Itonut (1983) Ltd. 2009

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters